Vertex Pharmaceuticals (Australia)

FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain

FDA · moderate-to-severe acute pain · 7 min

The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.

FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx

FDA · moderate-to-severe acute pain · 8 min

The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.

Vertex launches Journavx after FDA approval for acute pain

FDA · oncology · 9 min

Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.